Conventional treatments for obesity and diabetes, including metformin, GLP1 receptor agonists, and TZDs, lead to improvements in insulin sensitivity while also providing anti-inflammatory benefits. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.